A pharmacy and therapeutics (P&T) committee at a health maintenance organization is evaluating a newly approved oral anticoagulant for addition to the formulary. The new medication is being compared to the current standard of care, warfarin, for stroke prevention in patients with nonvalvular atrial fibrillation. The committee reviews the annual costs and health outcomes associated with both treatments.
The current standard of care (warfarin, including the cost of the drug, routine INR monitoring, and associated clinic visits) costs dollars per patient annually and provides an average of Quality-Adjusted Life Years (QALYs) per year.
The new oral anticoagulant costs dollars per patient annually (including drug costs and minimal required monitoring) and provides an average of QALYs per year due to a lower incidence of major bleeding events and improved patient adherence.
Based on this data, what is the incremental cost-effectiveness ratio (ICER) of the new oral anticoagulant compared to the standard of care? (Express your answer in dollars per QALY gained as a whole number).
Answer: 80000 $/QALY